Want to see AU:VBS full AI Analyst Report?
VBS Stock Chart & Stats
AU$0.18
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.18
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.46
Previous CloseN/A
Volume32.26K
Average Volume (3M)97.35K
Market Cap
AU$9.90M
Enterprise ValueAU$8.15M
Total Cash (Recent Filing)AU$330.50K
Total Debt (Recent Filing)AU$467.10K
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding61,867,050
10 Day Avg. Volume169,215
30 Day Avg. Volume97,349
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-8.29
Price to Sales (P/S)4.45
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA consistently very high gross margin profile provides durable unit economics: once revenue stabilizes, gross profits can cover fixed R&D and G&A. Over the medium term this supports scalable margin expansion and gives management leverage to prioritize profitable product lines or partnerships.
Modest Absolute DebtModest absolute debt reduces near-term interest obligations and lowers immediate default risk. This structural benefit gives management flexibility on timing of financing or strategic transactions, and limits fixed financial burden while the company pursues longer-term development or commercialization milestones.
Improving Cash Burn TrendAn improvement in cash burn shows progress toward operational discipline or better cost/revenue balance. If sustained, this trend extends runway, reduces frequency of dilutive raises, and increases the chance management can reach de-risking milestones before needing significant external capital.
Bears Say
Shrinking RevenueA 45.9% revenue decline is a structural red flag: it erodes scale, weakens pricing leverage, and increases per-unit fixed cost absorption. Over several quarters this trend materially lengthens the path to breakeven, undermines investor confidence, and raises the likelihood of repeated capital raises.
Persistent Negative Cash FlowConsistently negative operating and free cash flow means reported losses translate into real cash drains. With free cash flow roughly tracking net losses, the business depends on external financing to sustain operations, limiting strategic options and increasing dilution and refinancing risk over the medium term.
Negative Shareholders' EquityNegative shareholders' equity reflects accumulated losses exceeding capital and materially weakens the balance sheet. This distorts leverage ratios, reduces borrowing capacity, and raises funding risk; restoring solvency will likely require equity injections that dilute existing holders.
Vectus Biosystems Limited News
VBS FAQ
What was Vectus Biosystems Limited’s price range in the past 12 months?
Vectus Biosystems Limited lowest share price was AU$0.05 and its highest was AU$0.46 in the past 12 months.
What is Vectus Biosystems Limited’s market cap?
Vectus Biosystems Limited’s market cap is AU$9.90M.
When is Vectus Biosystems Limited’s upcoming earnings report date?
Vectus Biosystems Limited’s upcoming earnings report date is Sep 02, 2026 which is in 20 days.
How were Vectus Biosystems Limited’s earnings last quarter?
Vectus Biosystems Limited released its earnings results on Feb 26, 2026. The company reported -AU$0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.014.
Is Vectus Biosystems Limited overvalued?
According to Wall Street analysts Vectus Biosystems Limited’s price is currently Overvalued.
Does Vectus Biosystems Limited pay dividends?
Vectus Biosystems Limited does not currently pay dividends.
What is Vectus Biosystems Limited’s EPS estimate?
Vectus Biosystems Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vectus Biosystems Limited have?
Vectus Biosystems Limited has 61,867,050 shares outstanding.
What happened to Vectus Biosystems Limited’s price movement after its last earnings report?
Vectus Biosystems Limited reported an EPS of -AU$0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Vectus Biosystems Limited?
Currently, no hedge funds are holding shares in AU:VBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vectus Biosystems Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
143.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-62.59%
Trailing 12-Months
Company Description
Vectus Biosystems Limited
Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
Technical Analysis
Acrux
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―